Byotrol Share Discussion Threads

[sikhthetech] 28/2/2020 09:55

Kcowe,

You've got me on filter remember or was that just another lie...doh!!
Who were YOU fooling..lol

You on sentry duty today??? Same as the gang blnx/rthm/trmr.. eh...



kcowe - 06 Feb 2020 - 12:43:47 - 4227 of 4677 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT
Dont know what your saying sikh... you are on filter ,as you are an irritation.

[kcowe] 28/2/2020 09:53

sloppy sloppy advise your credibility is zero

[kcowe] 28/2/2020 09:52

you have been slating this since 1.7p days .... market is in free fall ... byot rises

[kcowe] 28/2/2020 09:50

gang moves on... at what price lol.... 10- 20 30 p a share .

[sikhthetech] 28/2/2020 09:47

kcowe,

"who is the bigger fool "

Those who will be trapped in once the gang move on...

Happens so many times, pumped and dumped...
I heard it all before from you lot on the blnx/rthm thread...

[a.fewbob] 28/2/2020 09:39

Yeah, I think he’s seriously underwater.

No way would anyone else post on here 24/7 unless they were in serious trouble.

[kcowe] 28/2/2020 09:38

up 11% on a day when the market is down almost 4% who is the bigger fool sikh lol...

[sikhthetech] 28/2/2020 09:33

Byot's 1 product at Boots has been sold out for nearly 4 weeks!! So loss of potential sales during a crucial period of the outbreak...






Look at their revenues from consumer division anyway.

Interims:
According to their interims, published only 2 months ago, revenues for H1 from consumer segment were only £410k, which included a contribution from Tescos, a contract they have lost.

so consumer REVENUES were about £35k from non-Petcare for the 6 months.


Even a 10 fold increase in consumer sales, ex petcare will only be around £350k revenues over 6 months.


Given Byot based Boots product has been sold out for 4 weeks, I doubt they will significantly increase consumer, ex petcare, revenues.




"Headline H1 revenues in this segment were £0.41m versus £0.45m in H1 2018 (as restated). Petcare remains the largest element of day-to-day sales in consumer, accounting for 92% of consumer sales in the period."

[a.fewbob] 28/2/2020 09:32

Have you run out of shorting funds yet?

[kcowe] 28/2/2020 09:27

price still going up sikh! why is that lol....

[sikhthetech] 28/2/2020 09:08

"listen to doctors advise "

says it all really...

Please listen to the long term BYOT holders but not to any official advice..

Honest guv..
;-)

[kcowe] 28/2/2020 08:57

sikhthetech....obvious is obvious why are you not able to see ...?

[kcowe] 28/2/2020 08:55

Listen to doctors advise .. one ends up dead ... lol

[sikhthetech] 28/2/2020 08:54

"byot up"

SP can be manipulated, company/industry news can't..

[kcowe] 28/2/2020 08:46

markets getting battered ... byot up lol... none of the above compete with byotrol
why do you think I bought loads ... saw this coming .. forget what is said . look at what is being done .

[sikhthetech] 28/2/2020 08:35

If you were looking for hand sanitiser, would you follow WHO, CDC advice to use an Alcohol based sanitiser or would you use Byot's non-alcohol based sanitiser?

Obviously the public would ignore WHO/CDC advice and listen to BYOT...

honest guv...
;-)



WHO:

"Wash your hands frequently with soap and water or use an alcohol-based hand rub if your hands are not visibly dirty."




CDC:

"If soap and water are not readily available, use an alcohol-based hand sanitizer with at least 60% alcohol. Always wash hands with soap and water if hands are visibly dirty."




Dettol:

"If soap and water are not available, use an alcohol-based hand sanitizer"

[kcowe] 28/2/2020 08:30

sikh... moan as much as you want....alcohol cannot compete with byotrol products ..
That is a fact ... and a pandemic is what we have already got ..

[sikhthetech] 27/2/2020 22:39

Slice,

"The backdrop of a declining share price due entirely to inst selling is compelling to patient investors."

Really, entirely due to II selling...so putting into reader's minds and backing up what 1gw said about II need to put their money somewhere, suggesting that Byot is a good place for their money, eh...


Obviously the selling has nothing to do with:


The share price is higher than last May, before the long slide..
The issues causing the share price slide are still there..



Last May when the share price was lower:

1) Byot were close to signing a 2nd national retailer
2) Byot had the Tesco contract which served them well
3) No one was expecting any accounting irregularities
4) Trial at Target extended to more sites and was expecting even more.
etc


Now the share price is higher but:
1) 2nd national retailer NEVER SIGNED, WHY?
2) Byot LOST the TESCO CONTRACT, no replacement announced
3) ACCOUNTS NOT QUALIFIED
4) appointed an agency (costing money) in US and STILL seeking partnerships
5) Trial at Target ENDS NEXT month but so far not rolled out to all stores..
etc etc

The share price is now significantly higher based on HOPE and without any of those issues, which caused the share price to fall, being resolved.


Honest Guv!!!

[sikhthetech] 27/2/2020 22:36

"Do you think this is a good time to be looking for an investment partner in the US who can put serious marketing resource into a road-tested new consumer product"

No I don't actually...

They've been seeking a partner for months....
It's been 2 months since the outbreak was announced...

Once they find a US partner then it'll be weeks before they sort out the logistics and have a supply chain is in place...


So it's more of MAYBE THEY'RE TOO LATE FOR COVID-19.

But let's see if they announce anything over the next week...

[mutley28] 27/2/2020 22:23

You can buy from Medimark's website

[slicethepie] 27/2/2020 22:21

Good overview. I think you are correct that long term investors are attracted by the turnaround that DT had overseen which includes attracting a top drawer chairman and a premier league marketing guru. The backdrop of a declining share price due entirely to inst selling is compelling to patient investors.

[1gw] 27/2/2020 22:18

Do you think this is a good time to be looking for an investment partner in the US who can put serious marketing resource into a road-tested new consumer product which "eliminates OVER 99.9% of germs and keeps surfaces sanitized for 24 HOURS with a revolutionary NON-TOXIC cleaning formula"?

And if financial terms with a partner are already all but nailed down, and can't be reopened, do you think this would be a good time to launch such a product nationally?

What about Solvay and Actizone? Do you think the current environment might push them into getting their finger out and doing a proper launch of a product based on that technology?

It seems to me that the 24-hour claim might be particularly attractive in the current environment.

[sikhthetech] 27/2/2020 21:58

Byot's 1 product at Boots has been sold out for nearly 4 weeks!! So loss of potential sales during a crucial period of the outbreak...






Look at their revenues from consumer division anyway.

Interims:
According to their interims, published only 2 months ago, revenues for H1 from consumer segment were only £410k, which included a contribution from Tescos, a contract they have lost.

so consumer REVENUES were about £35k from non-Petcare for the 6 months.


Even a 10 fold increase in consumer sales, ex petcare will only be around £350k revenues over 6 months.


Given Byot based Boots product has been sold out for 4 weeks, I doubt they will significantly increase consumer, ex petcare, revenues.




"Headline H1 revenues in this segment were £0.41m versus £0.45m in H1 2018 (as restated). Petcare remains the largest element of day-to-day sales in consumer, accounting for 92% of consumer sales in the period."

[1gw] 27/2/2020 21:46

Not many places to hide in this market. Apart from investors throwing in the towel on individual stocks, I guess lots of money is being pulled, or is going to be pulled, from funds - which may then force institutional selling on a fairly indiscriminate basis.

So byotrol potentially is a winning stock on two counts: products for which demand seems likely to grow as the coronavirus incidence becomes more widespread (so "a place to hide" in the market); and not much of an institutional base.

And that's on top of the underlying investment case (the reason I and I suspect many of the longer-term holders have been buying over the last few years) built around turnaround of the business under David Traynor's leadership through tight control of costs, development of IP that is at the leading edge of regulatory change, getting regulatory approval for products based on that IP and now (through the Medimark acquisition) moving into sales and marketing, with major upside possible through licensing/partnership deals.

Now where's that US deal?